AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$ZTS

Zoetis (NYSE:ZTS) posts better-than-expected sales in Q3 2026

Zoetis (ZTS) reported Q3 2026 revenue of $2.39B, exceeding estimates by 2.6% and EPS of $1.75, beating estimates by 15.8%. The company raised its full-year revenue guidance to $9.27B and adjusted EPS guidance to $6.30.

Original reporting
finance.yahoo.com
Published Nov 5, 2026, 12:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 1:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Zoetis (NYSE:ZTS) posts better-than-expected sales in Q3 2026 — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ZTSBullishHigh
01

Why it matters

The beat and raised guidance reinforce the company's growth narrative, likely prompting buying interest.

02

Market read

Strong earnings and guidance lift ZTS and may boost the broader animal health sector.

03

What to watch

Potential supply‑chain constraints or upcoming regulatory reviews could temper upside.

Relevance 8/10Novelty 8/10Timing: pre‑market tomorrow

Background

Zoetis is the leading animal health company, and its quarterly results are closely watched by healthcare investors.

Company-level read

Ticker impact

$ZTSBullishHigh confidence
Context

Zoetis reported Q3 revenue of $2.39B beating estimates and raised full-year revenue and EPS guidance.

Expected impact

likely upside as investors price in the beat and raised guidance

Evidence & confidence

Both revenue and EPS beat expectations and guidance was lifted, a classic catalyst for a short-term rally.

Market effects

Sector

Animal health sector may see broader uplift as Zoetis sets a positive tone.

Regional

U.S. large‑cap healthcare stocks could benefit from the upbeat guidance.

Global

Zoetis' performance may influence global biotech and pharma sentiment.

Counterpoint

What could challenge this read

If the beat is already priced in, the stock could face profit‑taking pressure.

Key entities

  • Company
    Zoetis Inc.

    Animal health pharmaceutical company (NYSE:ZTS).

Read at source← All news

StoryZoetis reports Q3 2026 results, beats EPS and raises full‑year guidance

Also covered by

6 outlets

Related articles

$ZTSMedAI 8/10

Zoetis (ZTS) Q3 2026 Earnings Call Transcript

Zoetis (ZTS) reported Q3 2026 earnings with revenue and adjusted net income declining as expected. The company cited challenges in pet care due to rising costs and changing pet ownership trends, while livestock demand remains strong. Zoetis narrowed its full-year revenue guidance to the high end of its range and highlighted investments in key franchises and innovation.

finance.yahoo.com
$ZTSMedAI 8/10

Zoetis 3Q 2026: Revenue $2.39B, EPS $1.44 — 10-Q Summary

Zoetis reported 3Q 2026 revenue of $2.39B, down 1% YoY, and net income of $1.44B, down 18%. Declines were driven by softer U.S. companion-animal demand, competition, and lower prices, partially offset by livestock growth and favorable exchange rates. Higher restructuring costs also impacted earnings. U.S. companion-animal revenue fell 8%, while U.S. livestock and international revenues rose 5% and 4%, respectively.

tradingview.com
$ZTSHighAI 8/10

Why is Zoetis stock climbing today?

Zoetis (ZTS) stock rose 2.4% premarket after Q3 2026 earnings beat estimates, with adjusted EPS of $1.75 vs. $1.51 and revenue of $2.4B vs. $2.3B. The company raised full-year EPS guidance to $6.25–$6.35. International sales grew 4%, while U.S. companion animal business faced challenges. The stock traded near $91.30 premarket, below its 52-week high of $132.49.

investing.com